Differentiated Thyroid Cancer Whole-Body Scan Report

Study Type: [Post-therapy I-131 Whole-Body Scan / Diagnostic/Surveillance I-123 Whole-Body Scan / Diagnostic/Surveillance I-131 Whole-Body Scan]

Patient: [identifiers per institutional policy]

Study Date: [date of image acquisition]

Administration Date/Time: [date and time of radiopharmaceutical administration]

Interpreting Physician: [name and credentials]

Referring Physician: [name]

Clinical Indication

• [DTC histology] (e.g., papillary, follicular, Hürthle cell; state "not provided" if unknown)
• [Reason for study] (post-ablation staging, treatment response assessment, surveillance, or evaluation of rising Tg/abnormal imaging)
• [Thyroidectomy status and date]; [prior RAI therapy history with dates and activities]
• [Preparation method] (thyroid hormone withdrawal or rhTSH; low-iodine diet adherence; state "not provided" if unknown rather than omitting)
• [Relevant labs near administration] (TSH, Tg with stimulated/suppressed status, TgAb; state "not provided" if unknown)

Comparison

[Prior radioiodine whole-body scans and relevant anatomic imaging with dates] (If none available, state: "No prior radioiodine whole-body scan available for comparison.")

Technique

• [Radiopharmaceutical] (sodium iodide I-131 or I-123) [administered activity in mCi and/or MBq], [route]
• [Uptake interval from administration to imaging]
• [Imaging protocol] (whole-body planar anterior/posterior views; additional spot views if obtained)
• [SPECT/CT if performed] (regions imaged; CT purpose: attenuation correction/localization or diagnostic) (Include limitation statement if CT is low-dose or non-diagnostic.)
• [Technical limitations] (Only include if they affect interpretation, e.g., motion, contamination.)

Findings

Image Quality: [adequate / limited]; [significant artifacts or limitations affecting interpretation]

Thyroid Bed: [presence/absence of uptake]; [pattern: focal / diffuse; midline / lateralized]; [intensity: mild / moderate / intense]; [SPECT/CT localization if performed]; [interpretation: remnant thyroid tissue / suspicious for residual or recurrent disease / indeterminate]

Nodal Disease: [abnormal uptake outside the thyroid bed—laterality, nodal level, focality, and SPECT/CT correlation] (If no suspicious nodal uptake identified, state briefly.)

Distant Sites: [iodine-avid uptake by region if present—lungs with pattern and CT correlation, bones with anatomic landmark, mediastinum, or other sites; note if pulmonary lesions are below CT resolution] (If none, state briefly or omit.)

(Mention physiologic uptake only if it creates interpretive ambiguity. Include only clinically significant CT findings that impact interpretation.)

Impression

1. [Bottom-line statement of iodine-avid disease distribution]
2. [Thyroid bed interpretation: remnant / suspicious for residual or recurrent disease / indeterminate]
3. [Comparison to prior study: new / progressed / improved / stable] (Include only if prior study exists.)
4. [Statement that negative scan does not exclude non-iodine-avid disease] (Include only if structural disease is known but radioiodine uptake is absent.)
5. [Actionable recommendation tied to documented uncertainty] (e.g., correlate with Tg trend and neck ultrasound; consider FDG PET/CT if Tg-positive with negative radioiodine imaging) (Include only when a specific clinical question remains.)